促黄体生成素在辅助生殖技术的应用研究进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v4i2.5001
Abstract
近年来辅助生殖技术(Assisted Reproductive Technology,ART)发展迅速,控制性超促排卵(COH)治疗得到广泛应用。国内外众多实验和临床经验表明,卵泡生长不需要黄体生成素,但促黄体生成素(LH)对卵泡正常发育及卵母细胞成熟具有重要作用[1]。因此,在卵泡发育过程中恰当地应用LH、解决其添加的相关问题成为研究热点。本文将针对LH的作用及其在辅助生殖技术中的应用予以综述。
Keywords
促黄体生成素；辅助生殖技术；控制性超促排卵
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Alviggi,Carlo,Ferraretti,Anna Pia,Conforti,et al.Recom binant luteinizing hormone supplementation in assisted repr oductive technology: a systematic review[J].Fertility and Ste rility: Official Journal of the American Fertility Society, Pacific Coast Fertility Society, and the Canadian Fertility and Andrology Society,2018,109(4):644-664.
[2] FALCK B. Site of production of oestrogen in rat ovary as studied in micro-transplants.Acta Physiol Scand Suppl.1959; 47(163):1-101.
[3] O'Dea L,O'Brien F,Currie K,Hemsey G.Follicular develop ment induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect. Curr Med Res Opin. 2008 Oct;24(10):2785-93.
[4] Balasch J,Fábregues F.Is luteinizing hormone needed for optimal ovulation induction? Curr Opin Obstet Gynecol. 2002Jun;14(3):265-74.
[5] Shoham Z.The clinical therapeutic window for luteiniz ing hormone in controlled ovarian stimulation. Fertil Steril. 2002Jun;77(6):1170-7.
[6] Johnson S,Schiffner J,Freundl G,et al. Luteinising hormone profiles in conception and non-conception natural cycles. Eur J Contracept Reprod Health Care. 2019 Apr;24(2): 140-147.
[7] Ferraretti AP,Gianaroli L, Magli MC,et al. Exogenousluteinizing hormone in controlled ovarian hyperstimulationfor assisted reproduction techniques[J].Fertility and Sterility,2004,82(6):1521-1526.
[8] Levi-Setti Paolo Emanuele,Zerbetto Irene, Baggiani Annamaria,et al. An Observational Retrospective Cohort Trial on 4,828 IVF Cycles Evaluating Different Low Prognosis Patie nts Following the POSEIDON Criteria[J]. Front Endocrinol (Lausanne),2019(10):282.
[9] Bosch E, Labarta E, Crespo J, et al. Impact of lutein izing hormone administration on gonadotropin-releasing hor mone antagonist cycles: an age-adjusted analysis[J]. Fertili ty and sterility,2011,95(3):1031-1036.
[10] 骆丽华,刘雨生,季静娟,等.长方案卵巢刺激启动日血黄体生成素水平作为黄体生成激素添加指标的价值[J].中国实用妇科与产科杂志,2012,28(8):64-68.
[11] 梁秀霞,刘丽,贾玲玲.早卵泡期和晚卵泡期添加黄体生成素对多囊卵巢综合征GnRH-a长方案卵巢慢反应患者临床结局的影响[J].临床和实验医学杂志,2020,19(04):397-399.
[12] Bordewijk EM,Mol F,van der Veen F,Van Wely M.Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis[J].Hum Reprod Open, 2019,1(3):1-12.
[13] The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH) -indu ced follicular development in LH-and FSH-deficient anovul atory women:a dose-finding study[J].J Clin Endocrinol Metab, 1998,83:1507-1514.
[14] 周志明.重组人促黄体生成素在体外受精促排卵治疗中的应用[J].淮海医药,2021,39(1):69-71.
[15] Berker B, $ukiir YE, Ozdemir EU,et al. Human Menopausal Gonadotropin Commenced on Early Follicular Period Increases Live Birth Rates in POSEIDON Group 3 and 4 Poor Responders[J]. Reprod Sci, 2021,28(2):488-494.
[16] Younis JS,Laufer N.Recombinant luteinizing hormone supplementation to recombinant follicle stimulating hormone therapy in gonadotropin releasing hormone analogue cycles: what is the evidence? Curr Med Res Opin. 2018 May;34(5):881 -886.
[17] Lahoud R,Ryan J,Illingworth P,et al. Recombinant LH supplementation in patients with a relative reduction in LH levels during IVF/ICSI cycles: A prospective randomized controlled trial[J].Eur J Obstet Gynecol Reprod Biol,2017,210: 300-305.
[18] Oliveira JB,Mauri AL,Petemen CG,et al. Recombinant luteinizing hormone supplementation to recombinant follicle -stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol:a Meta-analysis[J].J Assist Reprod Genet,2007,24:67-75.
[19] Lehert P,Kolibianakis EM, Venetis CA,et al. Recombi nant human follicle-stimulating hormone (r-hFSH) plus reco mbinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systema tic review and meta-analysis. Reprod Biol Endocrinol. 2014 Feb 20;12:17.
[20] Humaidan P,Chin W,Rogoff D,et al. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized contro lled trial in poor ovarian responders. Hum Reprod. 2017 Mar 1;32(3):544-555.
[21] 李红真,龚斐,蔡素芬,等.卵巢刺激慢反应患者补充重组黄体生成素的疗效评价[J].生殖医学杂志,2013,22(02):92-96.
[22] YazcYlamz F,Grkemli H,Olakolu MC,et al. The evulation of recombination LH supplementation in patients with subopt imak response to recombinant FSH undergoing IVF treatment with GnRH agonist down-regulation[J].Gynecol Endocrinol,2015, 31:141-144.
[23] He W,Lin H,Lv J,et al. The impact of luteinizing horm one supplementation in gonadotropin-releasing hormone anta gonist cycles: a retrospective cohort study. Gynecol Endocrin ol.2018 Jun;34(6):513-517.
[24] Wang Y,Li L,Deng K,et al. Comparison of the combinat ion of recombinant follicle-stimulating hormone and recom binant luteinizing hormone protocol versus human menopausal gonadotropin protocol in controlled ovarian stimulation: A systematic review and meta-analysis[J].J Evid Based Med, 2020,13(3):215-226.
[25] Humaidan P,Bungum L, Bungum M,et al. Ovarian respon se and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation[J]. Human Reproduction,2002,17(8):2016-2021.
[26] Yu-Ting,Wan,Shan,Liu,Shan-Ke,et al.Effect of luteini zing hormone concentration on transcriptome and subcellular organelle phenotype of ovarian granulosacells.[J].Journal of assisted reproduction andgenetics,2021,38(4):809-824.
[2] FALCK B. Site of production of oestrogen in rat ovary as studied in micro-transplants.Acta Physiol Scand Suppl.1959; 47(163):1-101.
[3] O'Dea L,O'Brien F,Currie K,Hemsey G.Follicular develop ment induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect. Curr Med Res Opin. 2008 Oct;24(10):2785-93.
[4] Balasch J,Fábregues F.Is luteinizing hormone needed for optimal ovulation induction? Curr Opin Obstet Gynecol. 2002Jun;14(3):265-74.
[5] Shoham Z.The clinical therapeutic window for luteiniz ing hormone in controlled ovarian stimulation. Fertil Steril. 2002Jun;77(6):1170-7.
[6] Johnson S,Schiffner J,Freundl G,et al. Luteinising hormone profiles in conception and non-conception natural cycles. Eur J Contracept Reprod Health Care. 2019 Apr;24(2): 140-147.
[7] Ferraretti AP,Gianaroli L, Magli MC,et al. Exogenousluteinizing hormone in controlled ovarian hyperstimulationfor assisted reproduction techniques[J].Fertility and Sterility,2004,82(6):1521-1526.
[8] Levi-Setti Paolo Emanuele,Zerbetto Irene, Baggiani Annamaria,et al. An Observational Retrospective Cohort Trial on 4,828 IVF Cycles Evaluating Different Low Prognosis Patie nts Following the POSEIDON Criteria[J]. Front Endocrinol (Lausanne),2019(10):282.
[9] Bosch E, Labarta E, Crespo J, et al. Impact of lutein izing hormone administration on gonadotropin-releasing hor mone antagonist cycles: an age-adjusted analysis[J]. Fertili ty and sterility,2011,95(3):1031-1036.
[10] 骆丽华,刘雨生,季静娟,等.长方案卵巢刺激启动日血黄体生成素水平作为黄体生成激素添加指标的价值[J].中国实用妇科与产科杂志,2012,28(8):64-68.
[11] 梁秀霞,刘丽,贾玲玲.早卵泡期和晚卵泡期添加黄体生成素对多囊卵巢综合征GnRH-a长方案卵巢慢反应患者临床结局的影响[J].临床和实验医学杂志,2020,19(04):397-399.
[12] Bordewijk EM,Mol F,van der Veen F,Van Wely M.Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis[J].Hum Reprod Open, 2019,1(3):1-12.
[13] The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH) -indu ced follicular development in LH-and FSH-deficient anovul atory women:a dose-finding study[J].J Clin Endocrinol Metab, 1998,83:1507-1514.
[14] 周志明.重组人促黄体生成素在体外受精促排卵治疗中的应用[J].淮海医药,2021,39(1):69-71.
[15] Berker B, $ukiir YE, Ozdemir EU,et al. Human Menopausal Gonadotropin Commenced on Early Follicular Period Increases Live Birth Rates in POSEIDON Group 3 and 4 Poor Responders[J]. Reprod Sci, 2021,28(2):488-494.
[16] Younis JS,Laufer N.Recombinant luteinizing hormone supplementation to recombinant follicle stimulating hormone therapy in gonadotropin releasing hormone analogue cycles: what is the evidence? Curr Med Res Opin. 2018 May;34(5):881 -886.
[17] Lahoud R,Ryan J,Illingworth P,et al. Recombinant LH supplementation in patients with a relative reduction in LH levels during IVF/ICSI cycles: A prospective randomized controlled trial[J].Eur J Obstet Gynecol Reprod Biol,2017,210: 300-305.
[18] Oliveira JB,Mauri AL,Petemen CG,et al. Recombinant luteinizing hormone supplementation to recombinant follicle -stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol:a Meta-analysis[J].J Assist Reprod Genet,2007,24:67-75.
[19] Lehert P,Kolibianakis EM, Venetis CA,et al. Recombi nant human follicle-stimulating hormone (r-hFSH) plus reco mbinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systema tic review and meta-analysis. Reprod Biol Endocrinol. 2014 Feb 20;12:17.
[20] Humaidan P,Chin W,Rogoff D,et al. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized contro lled trial in poor ovarian responders. Hum Reprod. 2017 Mar 1;32(3):544-555.
[21] 李红真,龚斐,蔡素芬,等.卵巢刺激慢反应患者补充重组黄体生成素的疗效评价[J].生殖医学杂志,2013,22(02):92-96.
[22] YazcYlamz F,Grkemli H,Olakolu MC,et al. The evulation of recombination LH supplementation in patients with subopt imak response to recombinant FSH undergoing IVF treatment with GnRH agonist down-regulation[J].Gynecol Endocrinol,2015, 31:141-144.
[23] He W,Lin H,Lv J,et al. The impact of luteinizing horm one supplementation in gonadotropin-releasing hormone anta gonist cycles: a retrospective cohort study. Gynecol Endocrin ol.2018 Jun;34(6):513-517.
[24] Wang Y,Li L,Deng K,et al. Comparison of the combinat ion of recombinant follicle-stimulating hormone and recom binant luteinizing hormone protocol versus human menopausal gonadotropin protocol in controlled ovarian stimulation: A systematic review and meta-analysis[J].J Evid Based Med, 2020,13(3):215-226.
[25] Humaidan P,Bungum L, Bungum M,et al. Ovarian respon se and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation[J]. Human Reproduction,2002,17(8):2016-2021.
[26] Yu-Ting,Wan,Shan,Liu,Shan-Ke,et al.Effect of luteini zing hormone concentration on transcriptome and subcellular organelle phenotype of ovarian granulosacells.[J].Journal of assisted reproduction andgenetics,2021,38(4):809-824.
Copyright © 2022 杨蕾, 韩宝生, 秦玉宁
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License